---
schema_version: "secwatch.filing_event.v1"
accession: "0001816590-26-000047"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2026-07-07T10:33:23+00:00"
generated_at: "2026-07-07T10:35:09.358989+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Compass Pathways reports positive 26-week Phase 3 COMP006 data for COMP360 in TRD; NDA on track for Q4 2026

## Summary
- 39% of 25 mg arm achieved ≥25% MADRS reduction at Week 6, maintained through Week 26.
- Retreatment in Part B enhanced benefit: nearly 30% of responders at Week 6 later achieved remission.
- Safety profile generally well-tolerated; SAEs similar across arms (6.3% vs 5.7%).
- Rolling NDA submission with FDA on track for Q4 2026; launch anticipated H1 2027 subject to approval and DEA rescheduling.
- COMP006 enrolled 581 participants with highly chronic TRD (average depressive episode >3 years).

## SEC filing metadata
- accession: 0001816590-26-000047
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2026-07-07T10:33:23+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/0001816590-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001816590-26-000047
- JSON: https://secwatch.observer/filing/0001816590-26-000047.json
- Plain text: https://secwatch.observer/filing/0001816590-26-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.